Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo

Leukemia

Volumn 26, Issue 6, 2012, Pages 1365-1374

  Cocco, C ^a   Di Carlo, E ^b   Zupo, S ^c   Canale, S ^a   Zorzoli, A ^a   Ribatti, D ^d   Morandi, F ^a   Ognio, E ^c   Airoldi, I ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

cytokines; cytokines receptors; lymphoma

Indexed keywords

INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LARGE CELL LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHICKENS; CHORIOALLANTOIC MEMBRANE; DNA, NEOPLASM; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-17; INTERLEUKIN-23; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; POLYMERASE CHAIN REACTION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84862020826     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.363     Document Type: Article

References (60)

1. Nogai H, Dorken B, Lenz G. Pathogenesis of Non-Hodgkin's Lymphoma. J Clin Oncol 2011; 29: 1803-1811.
2. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large Bcell lymphoma. J Clin Oncol 2007; 25: 2426-2433. (Pubitemid 47007616)
3. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol 2010; 28: 2902-2913.
4. Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009; 2: 14.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833. (Pubitemid 28363048)
6. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
7. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423. (Pubitemid 40223656)
8. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992. (Pubitemid 46972781)
9. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004; 10: 5432-5438. (Pubitemid 39100480)
10. Khan KD, Emmanouilides C, Benson Jr DM, Hurst D, Garcia P, Michelson G et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 7046-7053. (Pubitemid 44974502)
11. Younes A, Sarris A, Consoli U, Rodriguez A, McLaughlin P, Huh Y et al. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood 1996; 87: 1698-1703. (Pubitemid 26068886)
12. Akamatsu N, Yamada Y, Hasegawa H, Makabe K, Asano R, Kumagai I et al. High IL-21. receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 2007; 256: 196-206. (Pubitemid 47418346)
13. de Totero D, Capaia M, Fabbi M, Croce M, Meazza R, Cutrona G et al. Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Exp Hematol 2010; 38: 373-383.
14. Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21. signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 2010; 115: 570-580.
15. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19: 641-644. (Pubitemid 37490789)
16. Shan BE, Hao JS, Li QX, Tagawa M. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol 2006; 3: 47-52.
17. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008; 180: 6527-6535.
18. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66: 8887-8896. (Pubitemid 44449207)
19. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006; 66: 6395-6404.
20. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176: 7317-7324. (Pubitemid 43849032)
21. Cocco C, Canale S, Frasson C, Di Carlo E, Ognio E, Ribatti D et al. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood 2010; 116: 3887-3898.
22. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010; 16: 4188-4197.
23. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
24. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-790. (Pubitemid 34786477)
25. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708. (Pubitemid 34556153)
26. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172: 2225-2231. (Pubitemid 38182370)
27. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y et al. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64: 1152-1156. (Pubitemid 38176923)
28. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008; 112: 750-759.
29. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007; 104: 3996-4001. (Pubitemid 47181567)
30. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-465. (Pubitemid 44264796)
31. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003; 171: 600-607. (Pubitemid 36871367)
32. Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, Ognio E et al. Interleukin-inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 2011; e-pub ahead of print 24 June 2011; doi:2010.1038/leu.2011.158.
33. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumors. IARC: Lyon, 2008.
34. Cocco C, Morandi F, Airoldi I. Interleukin-27 and interleukin-23 modulate human plasmacell functions. J Leukoc Biol 2011; 89: 729-734.
35. Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997; 34: 455-463. (Pubitemid 28008032)
36. Airoldi I, Di Carlo E, Banelli B, Moserle L, Cocco C, Pezzolo A et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004; 113: 1651-1659. (Pubitemid 39071689)
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
38. Larousserie F, Charlot P, Bardel E, Froger J, Kastelein RA, Devergne O. Differential effects of IL-27 on human B cell subsets. J Immunol 2006; 176: 5890-5897.
39. Johnson PW, Watt SM, Betts DR, Davies D, Jordan S, Norton AJ et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848-1857. (Pubitemid 23278776)
40. Paydas S. Anti-angiogenic strategies will be a revolution in lymphoma? Leuk Res 2010; 34: 552.
41. Koster A, van Krieken JH, Mackenzie MA, Schraders M, Borm GF, van der Laak JA et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154-161. (Pubitemid 40075790)
42. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010; 95: 2157-2160.
43. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Olsen ML, Funder AM et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584-595. (Pubitemid 46487768)
44. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 2008; 134: 381-387. (Pubitemid 351170060)
45. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 1647-1660.
46. Labidi SI, Menetrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T et al. Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Ann Hematol 2010; 89: 25-33.
47. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13: 575-582.
48. Pazgal I, Boycov O, Shpilberg O, Okon E, Bairey O. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma 2007; 48: 2213-2220. (Pubitemid 350091064)
49. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38-47.
50. Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C et al. Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 1992; 80: 498-504.
51. Tageja N, Padheye S, Dandawate P, Al-Katib A, Mohammad RM. New targets for the treatment of follicular lymphoma. J Hematol Oncol 2009; 2: 50.
52. Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A et al. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008; 7: 20.
53. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, al-Katib A. A unique EBVnegative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet 1993; 70: 62-67. (Pubitemid 23333303)
54. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM et al. A Phase 1b/2. trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 2010; 103: 1783-1787.
55. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 2008; 6: 1059-1070.
56. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248-256.
57. Alexandrakis MG, Pappa CA, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A et al. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med 2006; 17: 412-416. (Pubitemid 44572138)
58. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G et al. Th17 cells in cancer: help or hindrance? Carcinogenesis 2011; 32: 643-649.
59. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114: 1141-1149.
60. Lee YK, Mukasa R, Hatton RD, Weaver CT. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009; 21: 274-280.